Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Pierre Fabre Medicament · 2017
ClinicalTrials.gov · Datasets · License: Public Domain · 2017
Open Source ↗
epstein-barr virus+ associated post-transplant lymphoproliferative disease (ebv+ ptld), solid organ transplant complications, lymphoproliferative disorders, allogeneic hematopoietic cell transplant, stem cell transplant complications, epstein-barr virus (ebv)-associated lymphoproliferative disease (lpd), epstein-barr virus (ebv), cytotoxic t lymphocyte (ctl), cancer after transplant, kidney transplant, renal transplant, liver transplant
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 871373
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.